For Research Use Only  ·  Not for human, clinical, or veterinary use
Peptide Dosage Chart · Subcutaneous

How to Use Research Peptides

Remy Peptides stocks 14 research peptides — including retatrutide, BPC-157, TB-500, GHK-Cu and PT-141. This peptide dosage chart gives the subcutaneous (under-the-skin) research dose for each, how often it is dosed, and the honest, evidence-based pros and cons in plain language. Every figure is drawn from published research protocols and is provided for laboratory research reference only, not as human dosing advice.

14 products Route shown: Subcutaneous only Dose source: Peptpedia + clinical trials Verified July 2026
Metabolic / Fat loss Recovery Anti-Aging Immune Growth Hormone Blend Sexual Health Hormone Pink box = the under-the-skin (SC) research dose. mcg = microgram · mg = milligram · IU = international units.

Metabolic & Fat-Loss Peptides 4

Retatrutide

The strongest fat-loss research compound to date.

Fat Loss
Remy strengths10 · 20 · 30 · 40mg Pens · 10 & 40mg Vials

Subcutaneous Dose · research protocol

Dose2 mg → 12 mg
WhenOnce a week

Trials raised the dose gradually over several weeks. Every pen holds 300 clicks — the 30 mg pen = 0.1 mg/click; higher-strength pens deliver more per click. See the retatrutide dose calculator and pen-clicks guide for the exact per-click math.

Pros

  • Biggest weight loss in studies (~24%)
  • Also lowered blood sugar in trials
  • Large drop in liver fat

Cons

  • Nausea, vomiting or diarrhea
  • Faster heart rate
  • Skin tingling or numbness
Status: Experimental (Phase 3)View product

MOTS-c

Studied for metabolism, energy and exercise-like effects.

Metabolic
Remy strength10mg Vial

Subcutaneous Dose · research protocol

Dose~10 mg total
WhenSpread over a week

No clinical dose; mouse studies used mg/kg by IP injection. Community subQ is ~5–10 mg/week, so one 10 mg vial is about a week.

Pros

  • Studied for glucose metabolism
  • Activates the AMPK energy pathway
  • Exercise raises the body's own MOTS-c

Cons

  • Injection-site redness
  • Low blood-sugar feelings (shaky, dizzy)
  • Temporary tiredness
Status: ExperimentalView product

AOD-9604

GH fragment studied for fat loss without growth effects.

Fat Loss
Remy strength10mg Vial

Subcutaneous Dose · research protocol

Dose300–600 mcg
WhenOnce daily

Obesity trials were oral and results were modest; injectable use is anecdotal. One 10 mg vial is about 15–30 doses at 300–600 mcg.

Pros

  • Fat-focused GH fragment
  • Doesn't raise IGF-1
  • No growth-hormone side effects

Cons

  • Injection-site redness
  • Mild headache
  • Temporary tiredness
Status: ExperimentalView product

Tesamorelin

A growth-hormone releaser studied for belly & liver fat.

Metabolic
Remy strength10mg Vial

Subcutaneous Dose · research protocol

Dose2 mg
WhenOnce daily

Fixed 2 mg/day, no titration — the approved Egrifta dose. One 10 mg vial is about 5 days at 2 mg/day.

Pros

  • FDA-approved (belly-fat condition)
  • Cut visceral + liver fat in trials
  • Keeps growth hormone natural

Cons

  • Joint aches and stiffness
  • Injection-site redness or swelling
  • Fluid retention or puffiness
Status: FDA-approved (Egrifta)View product

Recovery & Healing Peptides 2

BPC-157

Studied for healing muscle, tendon and gut tissue.

Recovery
Remy strength10mg Vial

Subcutaneous Dose · research protocol

Dose~200–400 mcg
WhenOnce daily

No validated human dose. The ~200–400 mcg/day range is community-only; animal work used ~10 mcg/kg (a rat dose). One 10 mg vial is about 25–50 research doses.

Pros

  • Sped tissue & gut healing in studies
  • Helped form new blood vessels
  • Well tolerated in animal studies

Cons

  • Injection-site redness or irritation
  • Possible immune reaction (antibodies)
  • May spur unwanted blood-vessel growth
Status: ExperimentalView product

TB-500

Studied for recovery, flexibility and wound healing.

Recovery
Remy strength10mg Vial

Subcutaneous Dose · research protocol

Dose~1–2 mg
When1–2× per week

No human trials on this fragment; ~2–5 mg/week is a community figure. One 10 mg vial is about 2–5 weeks at that range.

Pros

  • Helped cells reach injury sites
  • Supported wound healing in studies
  • May aid heart tissue repair

Cons

  • Temporary tiredness or head-rush
  • Injection-site redness
  • May feed abnormal tissue growth
Status: ExperimentalView product

Anti-Aging Peptides 2

GHK-Cu

Copper peptide studied for skin, collagen and healing.

Anti-Aging
Remy strength50mg Vial

Subcutaneous Dose · research protocol

Dose~1–2 mg
WhenOnce daily

Most GHK-Cu research is topical; injected ~1–2 mg/day is community-only. One 50 mg vial is about 25–50 doses.

Pros

  • Boosted collagen in studies
  • Sped wound healing in studies
  • Antioxidant effects

Cons

  • Copper build-up with repeated use
  • Stinging or redness at the site
  • Nausea or lightheadedness
Status: ExperimentalView product

SS-31

Elamipretide — studied for cell-energy (mitochondrial) health.

Anti-Aging
Remy strengths10mg & 50mg Vials

Subcutaneous Dose · research protocol

Dose~4–10 mg
WhenOnce daily

Community research range that fits the 10 mg / 50 mg vials; human trials used a higher 40 mg/day SC. One 10 mg vial is about 1–2 days, a 50 mg vial about 5–12.

Pros

  • Targets cell energy directly
  • Lowers cell "rust" (free radicals)
  • FDA-approved for a rare disease

Cons

  • Injection-site pain and redness
  • Injection-site itching or hard lumps
  • Headache
Status: FDA-approved (Barth syndrome, 2025)View product

Peptide Blends 2

GLOW Blend

Three repair peptides in one pen for skin & recovery.

Blend
Remy strength70mg Pen (GHK-Cu 50 + BPC-157 10 + TB-500 10)

Subcutaneous Dose · research protocol

Dose1 click (2.5 mg)
WhenOnce daily

Deduced from the parts: one 2.5 mg click delivers ~1.8 mg GHK-Cu, ~0.36 mg BPC-157 and ~0.36 mg TB-500 — each within its own range above (TB-500 ≈ 2.5 mg/week). The 19-click pen is about a 19-day run.

Pros

  • Three repair peptides in one pen
  • No mixing or reconstitution
  • Covers skin + tissue research

Cons

  • Injection-site redness or swelling
  • Copper build-up with repeated use
  • Possible immune reaction
Status: ExperimentalView product

BPC-157 + TB-500

The two top healing peptides paired in one vial.

Blend
Remy strength5mg / 5mg Vial (10mg total)

Subcutaneous Dose · research protocol

Dose~250 mcg of each
When2–3× per week

Fixed 1:1 vial — each draw pulls equal BPC-157 and TB-500, so it can't dose them separately (use single vials for that). Community-only figures. One 5/5 mg vial is about 20 draws.

Pros

  • Covers fast + long-lasting repair
  • One vial, both peptides
  • Popular recovery combo

Cons

  • Injection-site redness or irritation
  • Temporary tiredness
  • May spur abnormal tissue growth
Status: ExperimentalView product

Growth-Hormone Peptides 1

CJC-1295 + Ipamorelin

Growth-hormone research stack for recovery & body composition.

Growth Hormone
Remy strength5mg / 5mg Vial (10mg total)

Subcutaneous Dose · research protocol

Dose~100–200 mcg of each
When1–3× daily

Non-DAC blend (short-acting), dosed daily, often fasted pre-bed. Frequent dosing empties a 5/5 mg vial fast — about 2–4 weeks.

Pros

  • Raises GH & IGF-1 together
  • Keeps GH release natural
  • Less cortisol rise than older GHRPs

Cons

  • Water retention or puffiness
  • Tingling or numb hands
  • Head-rush or hunger after dosing
Status: ExperimentalView product

Immune & Gut Peptides 1

KPV

Studied for calming inflammation in the body and gut.

Immune
Remy strength10mg Vial

Subcutaneous Dose · research protocol

Dose~100–200 mcg
WhenOnce daily

No standard dose; most research is oral or topical. ~100–200 mcg/day is community-only. One 10 mg vial is about 50–100 doses.

Pros

  • Anti-inflammatory in lab models
  • Studied for gut-barrier repair
  • Small, stable α-MSH tripeptide

Cons

  • Injection-site redness or itching
  • Possible mild allergic reaction
  • Occasional headache
Status: ExperimentalView product

Sexual-Health Peptides 1

PT-141

Bremelanotide — studied for sexual desire (works via the brain).

Sexual Health
Remy strength10mg Vial

Subcutaneous Dose · research protocol

Dose1.75 mg
WhenAs needed

Fixed 1.75 mg label dose, ~45 min before activity (community figures span 0.5–2 mg). Max once/24 h, up to 8×/month. One 10 mg vial is about 5–6 label doses.

Pros

  • FDA-approved for low sexual desire
  • Works via the brain, not blood flow
  • Different target than ED pills

Cons

  • Nausea and flushing
  • Short-term blood-pressure rise
  • Skin darkening with repeated use
Status: FDA-approved (Vyleesi)View product

Hormone Peptides 1

HCG

Hormone studied for testosterone and fertility support.

Hormone
Remy strength5,000 IU Vial

Subcutaneous Dose · research protocol

Dose500–3,000 IU
When2–3× per week

Measured in IU, not mg. One 5,000 IU vial is about 2–10 research doses depending on the amount used.

Pros

  • Strong fertility research record
  • Supports natural testosterone signal
  • Standardized by IU

Cons

  • Breast tenderness or swelling
  • Fluid retention and mood swings
  • Acne or oily skin
Status: Approved (fertility & male hypogonadism)View product
Common Questions

Frequently asked questions

How do you use research peptides?

Research peptides are reconstituted with bacteriostatic water (for vials) or dispensed by click (for pens) and administered subcutaneously — under the skin — at a compound-specific research dose on a set schedule. This peptide dosage chart lists that subcutaneous research dose, the dosing frequency, and the pros and cons for 14 peptides. Many research peptides have no established human dose and peptide dosage guidelines vary by compound, so every figure is for laboratory research reference only, not human dosing advice.

What does "subcutaneous" mean, and why is it the route shown here?

Subcutaneous (SC) means injected into the fat layer just under the skin. It is the most common route in peptide research protocols because it is simple and absorption is often in the 40–90% range, though it varies by compound — smaller molecules under 3 kDa typically absorb better than larger peptides. Several of these compounds are also studied topically, orally, or intraperitoneally.

How are peptide doses measured — mcg, mg, and IU?

Most research peptides are measured by mass in micrograms (mcg) or milligrams (mg), where 1 mg equals 1,000 mcg. HCG is the exception: it is measured in international units (IU), a standardized activity unit rather than a mass. How much bacteriostatic water you add at reconstitution then sets the concentration per draw, and on insulin syringes the unit markings show the volume drawn rather than the peptide mass itself.

How do you reconstitute a research peptide?

Reconstitution means adding bacteriostatic water to a lyophilised (freeze-dried) peptide vial to dissolve the powder before use, and the water volume you add determines the concentration per unit drawn. The pen formats need no reconstitution. See the bacteriostatic water guide for the exact reconstitution math.

How should research peptides be stored?

Lyophilised (freeze-dried) peptides are kept refrigerated and stay stable for months to years; once reconstituted, most are refrigerated and used within a few weeks. Keep them out of direct light and away from heat. See the peptide storage guide for compound-specific shelf life.

What is the difference between a peptide pen and a vial?

A pen is pre-filled and click-dosed — no mixing, and each click delivers a set amount. A vial is lyophilised powder you reconstitute with bacteriostatic water and draw with a syringe. Pens are simpler to use; vials give more flexibility over concentration.

Which of these peptides come ready to use, with no mixing?

The pen formats are ready to use — the retatrutide pens and the GLOW blend pen are click-dosed and need no reconstitution. Every vial format, including BPC-157, TB-500, GHK-Cu, KPV and the others, is lyophilised powder that must be reconstituted with bacteriostatic water first.

How is BPC-157 dosed in research?

In community research protocols, BPC-157 is used subcutaneously at roughly 200–400 mcg once daily, and there is no validated human dose. One 10 mg vial covers about 25–50 research doses. These figures are for laboratory research reference only, not human dosing advice.

How is TB-500 dosed in research?

TB-500, a thymosin beta-4 fragment, is used subcutaneously at about 1–2 mg once or twice weekly in community protocols (roughly 2–5 mg per week), with no human trials on the fragment itself. One 10 mg vial lasts about 2–5 weeks. For laboratory research reference only.

Which of these peptides are FDA-approved, and for what?

Four are FDA-approved for specific labeled uses: SS-31 (Barth syndrome), Tesamorelin (HIV-associated lipodystrophy), PT-141 (low sexual desire), and HCG (fertility and male hypogonadism). Every other compound in this guide, including retatrutide, is experimental and not approved for any use.

Do these research peptides have validated human doses?

Only the approved compounds have established clinical doses. BPC-157, TB-500, GHK-Cu, KPV, MOTS-c and the blends have no validated human dose — their ranges are anecdotal, community research figures — while retatrutide's doses come from its published Phase 3 trials.

Where do the doses in this guide come from?

Doses are compiled from Peptpedia and published clinical trials where they exist; peptides without a validated human dose show community research-protocol figures instead. Where trials exist, these peptide dosing protocols typically start low and titrate the dose upward over several weeks. Every figure is provided for in-vitro, laboratory research reference only, per UAE MoHAP Circular 17/2022 — not as human dosing advice.

How to read this & disclaimer

Only the subcutaneous (under-the-skin) research dose is shown, to keep things simple. For several compounds the main published research route is actually topical, oral or intraperitoneal (GHK-Cu, KPV, AOD-9604, BPC-157), so the injectable figures here are anecdotal. Each card is anchored to the exact product strength Remy Peptides stocks. Pharmacokinetics also shape these figures: most peptides have an elimination half-life around 2–8 hours, and renal clearance matters most for molecules under 5 kDa.

Dose source: Peptpedia (peptpedia.org/browse) and published clinical trials where they exist. Several peptides (BPC-157, TB-500, GHK-Cu, KPV, MOTS-c, and the blends) have no validated human dose — their ranges are anecdotal. HCG is not listed in Peptpedia; its figures come from published fertility research.

Verified July 2026 by an expert council review of doses and regulatory status. "Approved" items are approved only for their specific labeled medical use: SS-31 (Barth syndrome), Tesamorelin (HIV lipodystrophy), PT-141 (low sexual desire), HCG (fertility). All other products are experimental and not approved for any use.

Stock: Retatrutide 10 mg & 40 mg vials, the Retatrutide 40 mg pen, the BPC-157 + TB-500 blend, SS-31 50 mg, Tesamorelin, and HCG are currently out of stock (reference figures only); the 30 mg, 20 mg and 10 mg pens, the GLOW pen, SS-31 10 mg and the other vials are in stock.

Research use only: All doses are reported from published research protocols and are for laboratory research reference — they are not human dosing recommendations. Remy Peptides products are supplied strictly for in-vitro research use only, per UAE MoHAP Circular 17/2022.

Remy Peptides · remypeptides.com · July 2026

COA Library
Tracked Cold-Chain Delivery
Research Use Only